“In Phase 3 clinical trials, across a broad range of genotypes, once-daily ALYFTREK demonstrated non-inferiority to TRIKAFTA in ppFEV 1 response and statistically significant improvement in ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

I had realized my own mortality. The fact of the matter was, I was going to die. And young. This was pre-Trikafta so the average life expectancy for someone with CF was approximately 44 years old. My ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Participants were randomly assigned to receive Trikafta or placebo based on age and weight: Aged 6 to < 12 years and less than 30 kg: morning dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor ...